nifurtimox 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
5-nitrofuran derivatives	1929	23256-30-6

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

BAY A2502
lampit
Bayer 2502
nifurtimox

A nitrofuran thiazine that has been used against TRYPANOSOMIASIS.

Molecular weight: 287.29
Formula: C10H13N3O5S
CLOGP: -1.43
LIPINSKI: 0
HAC: 8
HDO: 0
TPSA: 106.02
ALOGS: -3
ROTB: 3

Status: ONP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.70	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	52.21 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
June 8, 2020	FDA	BAYER HEALTHCARE
Jan. 1, 1967	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	P01CC01	ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTIPROTOZOALS AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS Nitrofuran derivatives
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000977	Antiparasitic Agents
MeSH PA	D000981	Antiprotozoal Agents
MeSH PA	D014344	Trypanocidal Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infection by Trypanosoma cruzi	indication	77506005

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.17	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
120MG	LAMPIT	BAYER HEALTHCARE	N213464	Aug. 6, 2020	RX	TABLET	ORAL	Aug. 6, 2025	NEW CHEMICAL ENTITY
30MG	LAMPIT	BAYER HEALTHCARE	N213464	Aug. 6, 2020	RX	TABLET	ORAL	Aug. 6, 2025	NEW CHEMICAL ENTITY
120MG	LAMPIT	BAYER HEALTHCARE	N213464	Aug. 6, 2020	RX	TABLET	ORAL	Aug. 6, 2027	INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI
30MG	LAMPIT	BAYER HEALTHCARE	N213464	Aug. 6, 2020	RX	TABLET	ORAL	Aug. 6, 2027	INDICATED IN PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE AND WEIGHING AT LEAST 2.5 KG) FOR THE TREATMENT OF CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) CAUSED BY TRYPANOSOMA CRUZI

Bioactivity Summary:

None

External reference:

ID	Source
N0000167141	NUI
D00833	KEGG_DRUG
C0028073	UMLSCUI
CHEBI:7566	CHEBI
CHEMBL290960	ChEMBL_ID
DB11820	DRUGBANK_ID
D009547	MESH_DESCRIPTOR_UI
6842999	PUBCHEM_CID
12364	IUPHAR_LIGAND_ID
2615	INN_ID
M84I3K7C2O	UNII
2397986	RXNORM
200338	MMSL
29363	MMSL
d08076	MMSL
007487	NDDF
24869004	SNOMEDCT_US
714397006	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-750	TABLET, FILM COATED	30 mg	ORAL	NDA	29 sections
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-750	TABLET, FILM COATED	30 mg	ORAL	NDA	29 sections
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-750	TABLET, FILM COATED	30 mg	ORAL	NDA	29 sections
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-751	TABLET, FILM COATED	120 mg	ORAL	NDA	29 sections
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-751	TABLET, FILM COATED	120 mg	ORAL	NDA	29 sections
LAMPIT	HUMAN PRESCRIPTION DRUG LABEL	1	50419-751	TABLET, FILM COATED	120 mg	ORAL	NDA	29 sections